Elicio Therapeutics (ELTX) Other Operating Expenses (2020 - 2024)

Elicio Therapeutics has reported Other Operating Expenses for 5 years, with the latest figure at $3000.0 in Q1 2024.

• For the quarter ending Q1 2024, Other Operating Expenses changed N/A year-over-year to $3000.0; the trailing twelve-month figure through Dec 2024 stood at $3000.0 (changed N/A YoY), and the FY2024 full-year result was $3000.0, changed N/A from the prior year.
• Other Operating Expenses for Q1 2024 stood at $3000.0, down from $105000.0 in the prior quarter.
• The five-year high for Other Operating Expenses was $433000.0 in Q4 2021, with the low at -$3.1 million in Q4 2022.
• Historically, Other Operating Expenses has averaged -$431700.0 across 5 years, with a median of $115500.0 in 2020.
• Annual changes were most pronounced in 2021 — Other Operating Expenses soared 243.65% — and 2022, when it plunged 826.56%.
• Elicio Therapeutics' Other Operating Expenses stood at $126000.0 in 2020, then soared by 243.65% to $433000.0 in 2021, then sank by 826.56% to -$3.1 million in 2022, then surged by 103.34% to $105000.0 in 2023, then sank by 97.14% to $3000.0 in 2024.
• The last three Other Operating Expenses figures came in at $3000.0 (Q1 2024), $105000.0 (Q4 2023), and -$105000.0 (Q3 2023), per Business Quant data.